This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gelber, R H Articles by Brennan, P J Search for Related Content PubMed PubMed Citation Articles by Gelber, R H Articles by Brennan, P J

 Previous Article  |  Next Article 

Infection and Immunity, October 1994, p. 4250-4255, Vol. 62, No. 10
0019-9567/1994/$04.00+0     DOI:

research-article

Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads.

Medical Research Institute of California Pacific Medical Center, San Francisco.

ABSTRACT

In this study, we evaluated vaccination with a number of purified, as well as recombinant, Mycobacterium leprae proteins for protective efficacy in mice. BALB/c mice were immunized intradermally with various native somatic (purified) or recombinant M. leprae proteins and their synthetic polypeptides emulsified in Freund's incomplete adjuvant. The protective efficacy of these preparations was assessed by enumeration of bacilli in the footpads of mice challenged with viable M. leprae 1 to 2 months following immunization. Protection was afforded by the purified and recombinant 10-kDa M. leprae cytoplasmic heat shock protein, the recombinant cell wall-associated 65-kDa M. leprae heat shock protein, and to a lesser extent, the purified 28-kDa M. leprae cytoplasmic protein (superoxide dismutase). Vaccination with either the purified or recombinant 35-kDa M. leprae cell membrane protein, the synthetic 27-amino-acid N-terminal peptide of the 10-kDa protein, the recombinant 18-kDa M. leprae protein, or the purified 22-kDa cell membrane protein was ineffective. When the interval between immunization and challenge was increased to 6 months, the purified 10-kDa M. leprae protein and the recombinant 65-kDa M. leprae protein lost vaccine efficacy, while a sodium dodecyl sulfate-soluble protein fraction of the M. leprae cell wall (soluble proteins), as had been found previously, continued to protect, suggesting that multiple M. leprae protein epitopes are critical for solid vaccine protection.

This article has been cited by other articles:

• Ngamying, M., Sawanpanyalert, P., Butraporn, R., Nikasri, J., Cho, S.-N., Levy, L., Brennan, P. J. (2003). Effect of Vaccination with Refined Components of the Organism on Infection of Mice with Mycobacterium leprae. Infect. Immun. 71: 1596-1598 [Abstract] [Full Text]  
• Mustafa, A. S., Lundin, K. E. A., Meloen, R. H., Shinnick, T. M., Oftung, F. (1999). Identification of Promiscuous Epitopes from the Mycobacterial 65-Kilodalton Heat Shock Protein Recognized by Human CD4+ T Cells of the Mycobacterium leprae Memory Repertoire. Infect. Immun. 67: 5683-5689 [Abstract] [Full Text]